Harvey Adams

Partner at Carpmaels & Ransford LLP

Harvey Adams is a partner who focuses on the life sciences and chemistry sectors. With over 20 years’ experience at first-instance and appellate level, he is recognised as one of the leading attorneys and advocates in contentious proceedings before the EPO and is a respected strategist and formidable opponent. Mr Adams brings a wealth of knowledge and insight to any contentious matter and has therefore been entrusted with the defence of many important patents for landmark drugs, especially in the context of parallel or anticipated abbreviated new drug application litigation. In addition to his work in the contentious arena, Mr Adams is adept at navigating freedom-to-operate issues and devising prosecution strategies to maximise the strength and reach of clients’ intellectual property. Mr Adams has extensive experience with due diligence matters and an in-depth knowledge of:

  • regulatory data protection;
  • orphan drug designations;
  • clinical trial exemptions; and
  • patent term extensions such as supplementary protection certificates.

Mr Adams’s practice focuses on biotechnology and pharmaceuticals, including but not limited to:

  • new chemical entities and prodrug technology;
  • protein and peptide therapeutics;
  • antibodies immunoconjugates and antibody drug conjugates;
  • antisense oligonucleotides;
  • gene therapy;
  • glycoengineering;
  • cell and tissue culturing; and
  • protein and peptide display platforms. 

In addition to cases directed to application programming interfaces, he has been heavily involved in second and third generation patents on:

  • drug formulations;
  • drug delivery systems;
  • polymorphs;
  • dosing regimens; and
  • pharmacokinetics. 

Mr Adams has defended many important patents protecting landmark drugs such as:

  • Avonex (interferon beta);
  • Temodal (temozolomide);
  • Clarinex (desloratadine);
  • Humira (adalimumab);
  • Myozyme (alpha glucosidase);
  • Lexiva/Telzir (fosamprenavir);
  • Soliris (eculizumab);
  • Velcade (bortezomib);
  • Eloctate (recombinant Factor VIII);
  • Alprolix (recombinant Factor IX);
  • Norvir (ritonavir);
  • Kaletra (ritonavir and lopinavir);
  • Constella (linaclotide); and
  • Ninlaro (ixazomib citrate). 

Mr Adams also practises in the nutritional composition, cosmetic, cosmeceutical and diagnostic fields.

Firm details

Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA
United Kingdom

Contact details

See firm profile